Daily Brief Health Care: Zoetis Inc, Mettler-Toledo International I, Immix Biopharma Inc, Shanghai Medicilon and more

• Zoetis is the global leader in the animal health industry. It discovers, develops, manufactures and commercializes medicines, vaccines, diagnostic products and services.
• Zoetis counts with over 300 product lines, with 15 of them generating over 100M in annual sales.
• The latter are called blockbusters, and the company holds

Key points (machine generated)

• Mettler-Toledo attracts a wide range of customers, from large corporations to individual researchers, by providing significant value and profitability for the company.
• The company’s business model is highly resilient, as 80% of its revenue comes from recurring sales of consumables, services, and software, ensuring stable cash flow.
• Mettler-Toledo has a strong track record of innovation, developing new products and solutions that address customer needs and industry trends, such as automation and digitization. 

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Immix Biopharma has released back-to-back updates, including EU orphan drug designation (ODD) for its lead CAR-T asset NXC-201, addressing amyloid light chain amyloidosis (ALA), and pricing of its $15m equity raise. This follows on the heels of the ODD grant for its lead asset by the FDA for two indications, ALA and multiple myeloma (MM), in H223. The EU ODD includes up to 10 years of EU market exclusivity (post-approval), reduced regulatory fees and access to the EU centralized authorization procedure. Achieving ODD in ALA in the EU is a key step forward for the clinical development of NXC-201. We believe the next readout from the ongoing NEXICART-1 trial and dosing of patients at US trial sites (NEXICART-2) across H124 will be the key upcoming catalysts for the company.

• NHSA’s new regulation on establishing a mechanism for pricing newly listed chemical drugs and encouraging high-quality innovation attracted widespread attention. However, it’s difficult to interpret this as an optimistic rule.
• Although we see increasing interest in products from Chinese pharmaceutical companies, it would be difficult for Chinese biotech to be acquired on a large scale in the foreseeable future.
• Based on 2023 results, Medicilon has entered a vicious circle. Multiple sell-offs made us question the moral standards of management. The risk is high for this type of small/lower-tier CXO.